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ABSTRACT In animal models, the cardiotropic hor-
mone relaxin has been shown to protect the heart against
ischemia and reperfusion-induced damage, acting by
multiple mechanisms that primarily involve the coronary
vessels. This in vitro study evaluates whether relaxin also
has a direct protective action on cardiac muscle cells.
H9c2 rat cardiomyoblasts and primary mouse cardiomyo-
cytes were subjected to hypoxia and reoxygenation. In
some experiments, relaxin was added preventatively
before hypoxia; in others, at reoxygenation. To elucidate
its mechanisms of action, we focused on Notch-1, which is
involved in heart pre- and postconditioning to ischemia.
Inactivated RLX was used as negative control. Relaxin
(17 nmol/L, EC50 4.7 nmol/L), added 24 h before hypoxia
or at reoxygenation, protected against cardiomyocyte
injury. In fact, relaxin significantly increased cell viability
(assayed by trypan blue and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide), decreased apoptosis
(assayed by TUNEL and bax/bcl-2 ratio), and reduced
nitroxidative damage (assayed by nitrotyrosine expression
and 8-hydroxy-deoxyguanosine levels). These effects were
partly attributable to the ability of relaxin to upregulate
Notch-1 signaling; indeed, blockade of Notch-1 activation
with the specific inhibitor DAPT reduced relaxin-induced
cardioprotection during hypoxia and reoxygenation. This
study adds new mechanistic insights on the cardioprotec-
tive role of relaxin on ischemic and oxidative damage.—
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CARDIOVASCULAR DISEASE is the leading cause of death in
modern society worldwide (1). In particular, cardiac
dysfunction caused by nonlethal myocardial infarction
remains one of the most challenging clinical problems.
The pathogenic occurrences in the infarcted heart are
dependent on ischemia/reperfusion (I/R). The mecha-
nisms of I/R injury are complex and involve multiple
events, basically nitroxidative stress (2, 3) and inflamma-
tion (4), that play a key role in the progression of cardiac
damage and in the development of myocardial fibrosis
and heart failure (5). Hence, there is a major interest in
the identification of new therapeutic agents that can
prevent or reduce I/R-induced myocardial injury. In this
context, the hormone relaxin (RLX) emerges as a feasible
candidate. Best known for its effects on reproduction (6),
RLX has been validated as a bona fide cardiovascular
hormone (7–9). Studies in rats have shown that immu-
noreactive RLX is produced by cultured atrial cardiomyo-
cytes (10) and that RLX receptors are expressed by the
atrial and ventricular myocardium (11) and ventricular
cardiomyocytes (12). RLX is capable of enhancing cardiac
blood perfusion by dilating the preexisting coronary
vessels (13) and promoting neo-angiogenesis (14, 15).
The increased blood supply to the heart induced by RLX,
accompanied by its clear-cut anti-inflammatory (16–18)
and antifibrotic effects (15, 19–23), may account for the
protective action of RLX shown in animal models of
cardiac I/R. In these models, RLX markedly reduces
several myocardial injury parameters, the extension of
nonviable myocardium and fibrosis, thereby improving
cardiac contractile performance (15, 18, 20, 24–26).
Whether RLX may also behave as a direct protective
factor for cardiomyocytes is a tantalizing but poorly
explored matter. Indeed, this hypothesis is corroborated
by the findings that ventricular cardiomyocytes express
the specific RLX receptor RXFP1 (12) and that RLX
protects cardiomyocytes against oxidative stress-induced
apoptosis in vitro (27). A strictly related issue to investigate
is related to the intracellular mechanisms by which RLX
may exert cardioprotection. In this context, the Notch-1
pathway, which is involved in ischemic preconditioning
and postconditioning of the heart (28, 29) and in theAbbreviations: 8-OHdG, 8-hydroxy-2’-deoxyguanosine;
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reduction of I/R-induced cardiac nitroxidative stress (30),
holds a pivotal place. Notch-1 is a transmembrane
receptor that, once bound to its ligand, undergoes
proteolytic cleavages managed sequentially by ADAM 10
metalloprotease and the g-secretase complex. These
events allow the release of the intracellular domain of
Notch (Notch-ICD) that translocates to the nucleus to
control transcription of specific target genes (31). The
relationship between RLX and Notch-1 is supported by
the recent demonstration that RLX prevents the TGF-
b–induced transition of cardiac fibroblasts to myofibro-
blasts by activation of Notch-1 pathway (23).
The present study was designed to investigate the
possible protective actions of RLX on cardiac muscle cells
using an in vitro model of I/R, i.e., hypoxia followed by
reoxygenation (H+R), and to evaluate the possible
involvement of the Notch-1 pathway.
MATERIALS AND METHODS
Ethics statements
Animal handling and use complied with the European Com-
munity guidelines for animal care (DL 116/92, application
of the European Communities Council Directive of November
24, 1986; 86/609/EEC) and were approved by the Committee
for Animal Care and Experimental Use of the University of
Florence. The ethical policy of the University of Florence
conforms to the Guide for the Care and Use of Laboratory
Animals of the US National Institutes of Health (Publication No.
85-23, revised 1996; University of Florence assurance no. A5278-
01). The animals had free access to food and water and were
housed on a 12 h light/dark cycle at 22°C room temperature.
The experiments were designed to minimize pain and the
number of animals used. Killing was carried out by decapitation.
Cell culture and treatments
H9c2 embryonic rat myocardium-derived cells, a well-
characterized and widely used cell line to study myocardial
cell ischemia (32), were obtained from European Collection of
Cell Cultures (ECACC, Salisbury, United Kingdom). They were
cultured in DMEM (Sigma-Aldrich, Milan, Italy) supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen,
Carlsbad, CA, USA), 2 mM glutamine, 250 U/ml penicillin G,
and 250 mg/ml streptomycin (Sigma-Aldrich), in a humidified
atmosphere with 5% CO2 at 37°C. Primary cultures of mouse
ventricular immature cardiomyocytes were prepared from hearts
of 1-d-old newborn CD1 albino mice (Harlan, Correzzana, Italy),
as previously described (33). Briefly, hearts were excised, and
the ventricles were minced and digested at 37°C for 45 min in
calcium-free 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)-buffered Hanks’ solution, pH 7.4, containing 100 mg/
ml type II collagenase (Invitrogen). To reduce the harvest of
nonmyocardial cells, the tissue lysate was filtered through a 70
mm cell strainer (Millipore, Billerica, MA, USA) and preplated
for 1 h. The myocyte-enriched cells remaining in suspension
were seeded on collagen-precoated multiwell plates. Cardiomyo-
cytes were cultured in DMEM containing 10% horse serum, 5%
FBS, 2 mM glutamine, 250 U/ml penicillin G, and 250 mg/ml
streptomycin. In previous studies, these cells were characterized
morphologically, immunophenotypically, and electrophysiolog-
ically (33, 34) and were shown to express the specific RLX
family peptide receptor-1 (RXFP1) (34).
H9c2 cells and primary cardiomyocytes were subjected to
H+R, simulated in vitro by substrate starvation plus hypoxia
followed by reoxygenation as previously described (35) with
minor modifications. The cells were incubated in DMEM with
no serum or glucose and placed in a hypoxic chamber
saturated with a 0.1% O2, 5% CO2, 95% N2 gaseous mix,
humidified, and warmed at 37°C, for 7 h. At end hypoxia, the
cells were reoxygenated for 2 h by incubation in normoxic
conditions in glucose-containing, serum-free DMEM. Control
normoxic cultures were also prepared. Cells were treated or
not with human recombinant RLX (17 nmol/L), kindly
provided by the RRCA Relaxin Foundation (Florence, Italy),
administered in 2 different ways: in some experiments, RLX
was added preventatively, i.e., 24 h before hypoxia and
maintained for the whole duration of H+R (RLX+ H. and
RLX+H+R); in other experiments, RLX was added at re-
oxygenation, concurrently with the peak of ROS generation
(H+RLX+R). The noted RLX dose was chosen as the most
effective on the basis of preliminary dose-finding experiments
(5–50 nmol/ml) performed on H9c2 cell viability (data not
shown). These data were also used to determine RLX EC50.
As a control for specificity of the RLX effects on cell viability,
some experiments [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT) assay] were performed using inacti-
vated RLX (iRLX, 17 nmol/L) in the place of authentic RLX.
iRLX was obtained by blockade of functional arginine residues
by reaction with cyclohexanedione followed by dialysis of the
unbound reagent against distilled water, according to the
method of Bu¨llesbach and Schwabe (36). To test the effective
lack of bioactivity of iRLX, we measured cAMP generation in
human THP-1 cells constitutively expressing RXFP1, as pre-
viously described (37). These findings confirm that, at variance
with authentic RLX, iRLX did not induce any cAMP rise in THP-
1 cells (data not shown). The effects of iRLX were evaluated
at reperfusion, when authentic RLX showed the highest
cell protection.
To investigate the role of the Notch-1 pathway in the
mechanism of action of RLX, H9c2 cells were treated with N-
[N-(3,5 difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl es-
ter (DAPT; 5 mM, Sigma-Aldrich), a highly active g-secretase
inhibitor that blocks the generation of the Notch intracellular
domain (Notch-ICD), the active proteolytic fragment of Notch-1
receptor that mediates its biological effects. At the end of the
treatments, the cell cultures were photographed under a phase-
contrast inverted microscope.
Reverse transcription and real-time PCR
To evaluate whether H9c2 cells express RXFP1 mRNA, 1 mg
total RNA, extracted with TRIzol Reagent (Invitrogen), was
reverse transcribed and amplified with the SuperScriptOne-Step
RT-PCR System (Invitrogen). After cDNA synthesis for 30 min at
55°C, the samples were predenatured for 2min at 94°C and then
subjected to 38 cycles of PCR performed at 94°C for 15 s,
alternating with 57°C for 30 s and 72°C for 1 min; the final
extension step was performed at 72°C for 5min. The following rat
gene-specific primers were used: RXFP1 (NM_ 201417.1), forward
59-CGGATGGGATCTCCTCTCTT-39and reverse 59-GCGTGC
TTC CTG TAC TCT CC-39. PCR products were electrophoresed
on a 2% agarose gel stained with ethidium bromide.
To quantify bcl-2 and bax gene expression, 1 mg total RNA
was reverse transcribed with the iScript cDNA Synthesis Kit
(Biorad, Milan, Italy). Samples were incubated at 25°C for 5 min
followed by 30 min at 42°C and 5 min at 85°C. Appropriate
negative controls were carried out. Quantitative real-time PCR
was performed using iTaq Universal SYBR Green Supermix
(Biorad) on an ABI Prism 7900 HT detection system (Applied
Biosystems Foster City, CA, USA). PCR amplifications were
performed in Optical 96-well plates (Applied Biosystems) on
cDNA samples corresponding to a final RNA concentration of
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10 ng. The relative quantitation values of targets were nor-
malized to the endogenous GAPDH control gene. The primers
used in the current study were chosen from previously
published studies (38): bcl-2 (NM_016993.1) forward 59-GCT
ACG AGT GGG ATA CTG G-39 and reverse 59-GTG TGC AGA
TGC CGG TTC A-39; bax (NM_ 017059.2), forward 59-CTG
CAG AGG ATG ATT GCT GA-39 and reverse 59-GAT CAG CTC
GGG CAC TTT AG-39; and GAPDH (NM_017008.4), forward
59-AAC GGC ACA GTC AAG GCT GA-39 and reverse 59-ACG
CCA GTA GAC TCC ACG ACA T-39. Reaction conditions were
as follows: 95°C for 1 min, followed by 40 cycles at 95°C for 15 s
alternating with 55°C for 1 min for bax and GAPDH or 57°C for
1 min for bcl-2. PCR amplifications were run in triplicate. Blank
controls, consisting of no template (water), were performed in
each run. Melting curves were carried out to confirm amplifica-
tion of single sequences and absence of primer dimers. The
results of the real-time PCR data were represented as Ct values,
where Ct was defined as the PCR threshold cycle at which
amplified product was first detected. Ct values were analyzed
using the 22DDCt comparative method.
Western blotting
After treatments, H9c2 cells were lysed in cold buffer (10 mM
Tris/HCl, pH 7.4, 10 mM NaCl, 1.5 mM, MgCl2, 2 mM Na2
EDTA, 1% Triton X-100), added with 103 Sigmafast Protease
Inhibitor cocktail tablets (Sigma-Aldrich). On centrifugation at
13,000 3g for 20 min at 4°C, the supernatants were collected,
and the total protein content was measured spectrophotomet-
rically using the micro-BCA Protein Assay Kit (Pierce, IL, USA).
Forty micrograms of total proteins from cell lysates was electro-
phoresed by SDS-PAGE and blotted onto nitrocellulose mem-
branes (Amersham, Cologno Monzese, Italy). The membranes
were blocked with PBS containing 0.1% Tween (Sigma-Aldrich)
and 5% bovine serum albumin (AT-PBS; Sigma-Aldrich) for 1 h
at room temperature and incubated overnight at 4°C with rabbit
monoclonal anti-Notch-1 antibody (1:2000; Abcam) and rabbit
polyclonal anti-GAPDH antibody (1:1000; Cell Signaling Tech-
nology), assuming GAPDH as a control invariant protein.
Specific bands were detected using rabbit peroxidase-labeled
secondary antibodies (1:15,000; Vector Laboratories, Burlingame,
CA, USA) and ECL chemiluminescent substrate (Bio-Rad, Milan,
Italy). Densitometric analysis of the bands was performed using
Scion Image Beta 4.0.2 image analysis software (Scion Corpora-
tion), and the values were normalized to GAPDH.
Trypan blue viability assay
The trypan blue exclusion method was used to further assess cell
viability. H9c2 cells (5 3 104 per well) and primary cardiomyo-
cytes (3–5 3 104 per well, depending on the number of
littermates and the overall yielding of the isolation procedure)
were seeded in 24-well plates. At end treatments, the cells were
gently harvested and mixed with 0.4% Trypan blue solution
(Sigma-Aldrich); the resulting cell suspension was counted
under a phase-contrast inverted microscope using a Burker
chamber. The viable cells were expressed as percentage of the
total counted cells.
MTT viability assay
Cell viability wasmeasured using theMTT assay (Sigma-Aldrich).
H9c2 cells (5 3 104 per well) and primary cardiomyocytes
(3–5 3 104 per well) were seeded in 24-well plates. At end
treatments, MTT stock solution was added to each well and
incubated for 4 h at 37°C. Dimethyl sulfoxide was added to each
well to dissolve the formazan crystals. The plate was gently
shaken for 10 min and was read at 550 nm on a plate reader.
Optical density (OD) was assumed as an indicator of cell viability.
This assay was also used for evaluation of EC50 on increasing
RLX doses of 5, 17, and 50 nmol/L, corresponding to 5156 23,
973 6 73, and 550 6 27 OD, respectively.
TUNEL assay
H9c2 cells were grown on glass coverslips and subjected to the
different treatments. Cell death was studied with the TUNEL
assay for apoptosis, performed using a Klenow-FragEL DNA
fragmentation detection kit (Calbiochem, San Diego, CA, USA),
as reported in the manufacturer’s instructions. TUNEL-positive
nuclei were counted in 5 microscopic fields for each cell
preparation. TUNEL apoptotic index was then expressed as the
relative percentage of TUNEL-positive nuclei on the total
number of methyl green-stained nuclei.
Immunohistochemical localization of nitrotyrosine
Nitrotyrosine (NT), an index of protein nitrosylation by harmful
oxidants generated during inflammation, such as peroxynitrite,
was determined by immunocytochemistry as described previously
(39). H9c2 cells were grown on glass coverslips and subjected to
the different treatments. The cells were fixed with formaldehyde
for 10 min and then incubated with rabbit polyclonal anti-NT
antibody (1:118; Upstate Biotechnology, Buckingham, United
Kingdom) at 4°C overnight. The immune reaction was revealed
by goat anti-rabbit IgG conjugated with biotin (1:200; Vector
Laboratories), followed by incubation with ABC complex (1:200;
Vector Laboratories). Negative controls were carried out by
omitting the primary antibodies. Densitometric analysis of the
intensity of NT was performed on digitized images using Scion
Image Beta 4.0.2 in 20 regions of interest (ROI) of 100 mm2 for
each confocal stacks (at least 10).
Determination of 8-hydroxy-29-deoxyguanosine
8-Hydroxy-2’-deoxyguanosine (8-OHdG) levels, an indicator of
oxidative DNA damage, were determined in H9c2 cells using the
Highly Sensitive 8-OHdG Check (JaICA), according to the
manufacturer’s instructions. After treatment, the cells were
Figure 1. RT-PCR showing RXFP1 mRNA in H9c2 cells.
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collected with TRIzol Reagent (Invitrogen), and DNA was
isolated according to the manufacturer’s instructions. DNA was
then subjected to enzymatic digestion with 10 IU of P1 nuclease
(Sigma-Aldrich) in 10 ml and incubated for 1 h at 37°C with 5 IU
of alkaline phosphatase (Sigma-Aldrich) in 0.4 M phosphate
buffer, pH 8.8. All of the procedures were performed in the dark
under argon. Themixture was filtered by an AmiconMicropure-
EZ filter (Millipore), and 50 ml of each sample was used for
8-OHdG determination. The values are expressed as nanograms
8-OHdG per nanogram total DNA.
Confocal Immunofluorescence
H9c2 cells grown on glass coverslips were fixed with 0.5%
buffered paraformaldehyde for 10 min at room temperature.
After permeabilization with cold acetone for 3 min, the fixed
cells were blocked with 0.5% bovine serum albumin (Sigma-
Aldrich) and 3% glycerol in PBS for 20 min and then incubated
overnight at 4°C with a rabbit monoclonal anti–Notch-1
antiserum (1:200; Abcam), recognizing both Notch-1 receptor
and its activated form Notch- ICD. Immunoreactions were
revealed by specific anti-rabbit Alexa Fluor 488-conjugated IgG
(1:200; Molecular Probes, Eugene, OR, USA) for 1 h at room
temperature. Negative controls were carried out by replacing the
primary antibody with nonimmune serum; cross-reactivity of the
secondary antibody was tested in control experiments in which
primary antibodies were omitted. After washing, the immunola-
beled cells were mounted with an antifade medium (Biomeda
Gel Mount; ElectronMicroscopy Sciences, Foster City, CA, USA)
and observed under a confocal Leica TCS SP5 microscope
(Leica Microsystems, Mannheim, Germany) equipped with a
HeNe/Ar laser source for fluorescence measurements. Obser-
vations were performed using a Leica Plan Apo 633/1.43NA oil
immersion objective. Series of optical sections (1024 3 1024
pixels each; pixel size, 204.3 nm) 0.4 mm in thickness were taken
through the depth of the cells at intervals of 0.4mm. Images were
then projected onto a single “extended focus” image. Densito-
metric analysis of the intensity of Notch-ICD fluorescent signal
was performed on digitized images using the Scion Image Beta
Figure 2. Evaluation of H9c2 cell viability by trypan blue exclusion (A) andMTT (B) assay. Hypoxia (H) and evenmore reoxygenation
(H+R) cause a marked reduction of the amounts of viable cells. This effect was antagonized by RLX, given either 24 h before hypoxia
(RLX+H; RLX+H+R) or at reoxygenation (H+RLX+R), whereas iRLX had no effects. Representative phase contrast micrographs of
H9c2 cell monolayers (C) showing a marked reduction of cell amounts, as well as cell shrinkage and detachment, on hypoxia (H) and
H+R, whereas RLX reversed these effects. The cytoprotective effects of RLX were significantly reduced by the Notch-1 inhibitor DAPT.
Scale bars, 20 mm. Replicates of the experiments (n) are indicated at the bottom of each column. Values are mean6 SEM. Significance
of differences for trypan blue assay: aP, 0.001 vs. control; bP, 0.001 vs. H; cP, 0.001 vs. H+RLX; dP, 0.001 vs. control and P, 0.05
vs. H; eP , 0.001 vs. H+R; fP , 0.001 vs. RLX+H+R; gP , 0.001 vs. H+R; h, P , 0.001 vs. H+RLX+R. Significance of differences for
MTT assay: aP, 0.001 vs. control; bP, 0.01 vs. H; cP, 0.05 vs. H+RLX; dP, 0.001 vs. control and P, 0.01 vs. H; eP, 0.01 vs. H+R;
fP , 0.05 vs. RLX+H+R; gP , 0.01 vs. H+R; hP , 0.05 vs. H+RLX+R.
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4.0.2 image analysis program (Scion Corporation) in 20 ROI of
100 mm2 for each confocal stacks (at least 10).
Statistical analysis
The reported data are expressed as the mean6 SEM of at least 3
independent experiments. As the experimental values in each
group approximated to a normal distribution, statistical com-
parison of differences between groups was carried out using one-
way ANOVA followed by the Student-Newman-Keuls multiple
comparison test. P # 0.05 was considered significant. Calcu-
lations were done using the GraphPad Prism 2.0 statistical
program (GraphPad Software, San Diego, CA, USA).
RESULTS
RLX receptor is expressed by cardiac muscle cells
Primary mouse cardiomyocytes were previously found to
express RXFP1 (34). The present findings show that rat
cardiac muscle H9c2 cells also expressed RXFP1 mRNA
(Fig. 1).
RLX increases cardiac muscle cell viability impaired
by H+R
The Trypan blue exclusion test (Fig. 2A) showed that
hypoxia and especially reoxygenation caused a marked
reduction of H9c2 cell viability (20 6 1% and 10 6 2%
viable cells, respectively, the controls being 986 1%: P ,
0.001). RLX (17 nmol/L), added to the culture medium
24 h before hypoxia, significantly increased cell viability
both after hypoxia (60 6 1% viable cells, P , 0.001) and
after reoxygenation (48 6 1% viable cells, P , 0.001).
RLX also had protective effects when added at reoxyge-
nation (41 6 2% viable cells, P , 0.001). The beneficial
effects of RLX were significantly reduced, albeit not
abolished, when the Notch-1 inhibitor DAPT was admin-
istered together with the hormone, indicating that Notch-1
signaling is involved in the cardioprotective role of RLX
against cardiac injury (Fig. 2A).
Similar findings were obtained with the MTT assay (Fig.
2B), which showed that hypoxia and reoxygenation caused
a marked reduction of H9c2 cell viability (360 6 18 and
184 6 17 OD, respectively, the controls being 1060 6 60
OD; P , 0.001). RLX (17 nmol/L), added 24 h before
hypoxia, significantly increased cell viability both after
hypoxia (5116 31 OD, P , 0.01) and after reoxygenation
(325 6 31 OD, P , 0.05). RLX also had protective effects
when added at reoxygenation (313 6 17 OD, P , 0.05).
iRLX substituted for authentic RLX resulted in the disap-
pearance of any cytoprotective effect, as evaluated by the
MTT assay on H9c2 cells (Fig. 2B). The RLX-induced
cytoprotection plateaued above 17 nmol/L, showed an
estimated EC50 of 4.7 nmol/L, and weakened at higher
concentrations, although it was still present at 50 nmol/L.
Light microscopic observation of H9c2 cell monolayers
confirmed the above findings (Fig. 2C): in fact, the cell
amounts were markedly reduced and the individual cell
morphology worsened by hypoxia and H+R, whereas RLX
reversed the adverse effects. Coadministration of DAPT
reduced the effects of RLX.
The cardioprotective action of RLX against hypoxia-
and H+R-induced cell death was confirmed in parallel
experiments with primary cultures of mouse neonatal
cardiomyocytes subjected to Trypan blue exclusion and
MTT assays, which gave similar results as those performed
on H9c2 cells (Fig. 3A–B).
RLX protects cardiac muscle cells from nitroxidative
damage induced by H+R
RLX increased H9c2 cell viability by reducing nitro-
xidative stress occurring at reoxygenation (Fig. 4). In fact,
the levels of immunoreactive NT, a marker of protein
nitration that was enhanced on H+R (124 6 2 OD, the
controls being 95 6 1 OD: P , 0.001), were significantly
reduced after the addition of RLX, either before hypoxia
(112 6 1 OD: P , 0.001) or, at a lesser extent, at
Figure 3. Evaluation of the viability of mouse cardiomyocytes in
primary culture by trypan blue exclusion (A) andMTT (B) assay.
Hypoxia (H) and even more reoxygenation (H+R) cause
a marked reduction of the amounts of viable cells. This effect
was antagonized by RLX, given either 24 h before hypoxia
(RLX+H; RLX+H+R) or at reoxygenation (H+RLX+R). The
cytoprotective effect of RLX was significantly reduced by the
Notch-1 inhibitor DAPT. Replicates of the experiments (n) are
indicated at the bottom of each column. Values are mean6 SEM.
Significance of differences for trypan blue assay: aP, 0.001 vs. con-
trol; bP, 0.001 vs. H; cP, 0.01 vs. H+RLX; dP, 0.001 vs. control
and P , 0.05 vs. H; eP , 0.001 vs. H+R; fP , 0.01 vs. RLX+H+R;
gP , 0.001 vs. H+R; hP , 0.05 vs. H+RLX+R. Significance
of differences forMTT assay: aP, 0.001 vs. control; bP, 0.01 vs.
H; cP, 0.01 vs. H+RLX; dP, 0.001 vs. control and P, 0.01 vs.
H; eP, 0.001 vs. H+R; fP, 0.01 vs. RLX+H+R; gP, 0.01 vs. H+R;
hP , 0.05 vs. H+RLX+R .
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reoxygenation (118 6 2 OD: P , 0.05) (Fig. 4A). Similar
findings were observed in the experiments performed to
quantify oxidized DNA. The levels of 8-OHdG were
enhanced on H+R (1.8 6 0.1 ng/ng DNA, the controls
being 1 6 0.02 ng/ng DNA: P , 0.01) and were
significantly reduced after the addition of RLX, either
before hypoxia (0.9 6 0.1 ng/ng DNA: P , 0.001) or, at
a lesser extent, at reoxygenation (1.26 0.1 ng/ng DNA: P
, 0.01) (Fig. 4B). Of interest, the protective effects of
RLX against oxidative stress were reduced by DAPT
coadministration (Fig. 4A–B).
RLX protects cardiac muscle cells from apoptosis
induced by H+R
RLX significantly decreased apoptotic death induced by
hypoxia and reoxygenation in H9c2 cells. Indeed,
compared with the controls, mRNA expression of the
antiapoptotic gene bcl2 was reduced and that of the
proapoptotic gene bax enhanced by hypoxia and, even
more, by reoxygenation (Fig. 5). RLX, given both before
ischemia and at reperfusion, increased the expression of
bcl2 and decreased that of bax. The effects of RLX were
reduced by coadministration of DAPT (Fig. 5). Evaluation
of the percentage of TUNEL-positive apoptotic cells was
consistent with these findings (Fig. 6). Hypoxia and
especially reoxygenation caused a marked increase of
apoptosis (33 6 3% and 65 6 3% apoptotic cells,
respectively, the controls being 2.2 6 0.1%: P , 0.001).
RLX (17 nmol/L), added to the culture medium 24 h
before hypoxia, significantly decreased apoptosis both
after hypoxia (23 6 3% apoptotic cells, P , 0.001) and
after reoxygenation (386 4% apoptotic cells, P, 0.001).
RLX also had protective effects when added at reoxyge-
nation (486 2% apoptotic cells, P, 0.001). As expected,
coadministration of DAPT reduced the effects of RLX
(Figs. 5 and 6).
RLX stimulates the Notch-1 signaling pathway
The above findings indicate that inhibition of the Notch-1
signaling pathway reduces the cardioprotective effects of
RLX, suggesting a close functional relationship. Indeed,
a 24-h treatment of H9c2 cells with RLX (17 nmol/L)
induced a significant increase in Notch-ICD expression
(control, 40.9 OD; RLX, 72.3 OD; P , 0.001), the active
intracellular fragment of theNotch-1 receptor (Fig. 7A–B).
As expected, DAPT significantly reduced the basal ex-
pression of Notch-ICD (11.8 OD; P , 0.001) (Fig. 7A–B).
Of note, in the current experimental conditions, Notch-
ICD was down-regulated by hypoxia and, even more, by
reoxygenation (Fig. 7C–D), whereas RLX, given either
24 h before hypoxia or at reoxygenation, antagonized such
an effect (Fig. 7C–D).
DISCUSSION
Identification of the endogenous mechanisms that the
heart puts into play to increase its resistance to adverse
Figure 4. Evaluation of nitroxidative stress markers expressed by H9c2 cells in the different experimental conditions. Immunoreactive
nitrotyrosine (A), an index of protein nitration, and 8-OHdG (B), an index of DNA oxidation, were enhanced on H+R and
significantly reduced by the addition of RLX, given either 24 h before hypoxia (RLX+H+R) or at reoxygenation (H+RLX+R). The
protective effect of RLX was significantly reduced by the Notch-1 inhibitor DAPT. Scale bars, 10mm. Replicates of the experiments (n)
are indicated at the bottom of each column. Values are mean 6 SEM. Significance of differences for nitrotyrosine: aP , 0.001 vs.
control; bP , 0.001 vs. H+R; cP , 0.001 vs. RLX+H+R; dP , 0.05 vs. H+R; eP , 0.05 vs. H+RLX+R. Significance of differences for
8-OHdG: aP , 0.01 vs. control; bP , 0.001 vs. H+R; cP , 0.01 vs. RLX+H+R; dP , 0.01 vs. H+R; eP , 0.05 vs. H+RLX+R.
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conditions represents a new frontier of cardiologic re-
search. In this context, agents capable of modulating
these mechanisms to improve myocardial rescue on an
ischemic insult can be a promising therapeutic approach
(40). Among such agents, RLX deserves a pivotal place.
Convincing evidence exists in the literature that RLX,
which has been credited as a cardiotropic hormone (7–9),
protects the heart from ischemia and reperfusion-
induced myocardial damage in ex vivo and in vivo models
through its vasodilator, anti-inflammatory, and antifi-
brotic actions (15–23). The current findings provide the
first information that RLX also has a direct cytoprotective
effect on cardiac muscle cells subjected in vitro to hypoxia
and reoxygenation, increasing their resistance to oxygen
deprivation and nitroxidative stress. This finding is in
keeping with the observation that RLX protects cardio-
myocytes against oxidative stress-induced apoptosis (27).
The RLX-induced protection was observed both in H9c2
cells, a cardiac muscle lineage currently used as a model
for ischemic injury, and in primary cultures of freshly
isolated ventricular cardiomyocytes. In particular, our
findings demonstrate that the protective action of RLX is
receptor specific, because it is completely abolished by
iRLX and involves the activation of the Notch-1 signaling
pathway. Notch-1 is implicated in cardiac development,
where it regulates cardiomyocyte proliferation, myocar-
dial trabeculation, and valve formation (41, 42), as well as
in the maintenance of adult heart tissue integrity (43–45).
Notch signaling also plays a role in heart disease: its
expression increases in myocardial infarction (46, 47) and
in dilated or hypertrophic cardiomyopathy (48). Notch-1
activation contributes to cardioprotection afforded by
ischemic pre- and postconditioning and in the reduction
of ischemia/reperfusion-induced cardiac nitroxidative
stress in in vitro and in vivo animal models (28–30). The
present findings indicate that H9c2 cardiac muscle cells,
which express the high affinity RLX receptor RXFP1,
respond to RLX by up-regulating the expression of Notch-
ICD, the active intracellular domain of Notch-1. Indeed,
Notch-1 activation requires its proteolytic cleavage by
ADAM metalloproteases and g-secretase, causing the
release of Notch-ICD, which translocates into the nucleus
and stimulates the transcription of target genes control-
ling cell proliferation and maturation (49). In the present
experimental conditions, Notch-ICD expression was
markedly decreased in hypoxic and H+R-exposed H9c2
cells. RLX, added either 24 h before hypoxia or at
reoxygenation, was capable of significantly reducing the
Notch-ICD down-regulation. This mechanism plays a ma-
jor role in the cytoprotective action of RLX on cardiac
muscle cells. In fact, the capability of RLX to increase cell
viability by reducing H+R-dependent oxidative stress and
apoptosis is significantly hampered by coadministration of
DAPT, a g-secretase inhibitor that blocks the generation
of Notch-ICD (31). The fact that DAPT does not
completely abolish the effects of RLX may suggest that
multiple cytoprotective signaling pathways are operated
by RLX in cardiac muscle cells. For instance, these
pathways may involve the endogenous generation of nitric
oxide, a typical downstream effector of RLX (50), which
has been demonstrated to protect cardiomyocytes from
H+R-induced apoptosis (51). The possible mechanisms by
which RLX can activate the Notch-1 pathway remain to be
elucidated. It can be speculated that RLX may induce
ADAM 10 activation through a dual pathway that involves
the upregulation of Akt, a downstream pathway of RXFP1
activation (52) also involved in ADAM 10 activation (53),
and down-regulation of TIMP-1 (54), a known ADAM 10
inhibitor (55).
We point out that the present findings have been
obtained on cultured embryonic and neonatal cardiac
muscle cells, which may not exactly behave as adult
cardiomyocytes of the heart in vivo. Conversely, this fact
may suggest that RLX is capable of preserving viability of
the scattered population of cardiac stem cells of the adult
heart, favoring their postischemic activation as an attempt
to replace damaged cardiomyocytes. In this context, the
finding that RLX constitutively activates the Notch-1
pathway in H9c2 cardiac muscle cells may contribute to
explain the mechanisms whereby RLX promote neonatal
Figure 5. Evaluation of apoptosis-related genes expressed by
H9c2 cells in the different experimental conditions. Real-time
PCR shows that the mRNA expression of the antiapoptotic gene
bcl2 was reduced and that of the proapoptotic gene bax was
enhanced by hypoxia (H) and even more reoxygenation (H+R).
These changes were antagonized by RLX, given either 24 h
before hypoxia (RLX+H; RLX+H+R) or at reoxygenation
(H+RLX+R). The Notch-1 inhibitor DAPT reduced the effects
of RLX. The columns represent fold changes over the corre-
sponding values of the control cultures, assumed as 1. Replicates
of the experiments (n) are indicated at the bottom of each
column. Values are mean 6 SEM. Significance of differences for
bcl-2: aP, 0.001 vs. control; bP, 0.01 vs. H; cP, 0.01 vs. H+RLX;
dP , 0.001 vs. control and P , 0.001 vs. H; eP , 0.001 vs. H+R;
fP, 0.01 vs. RLX+H+R; gP, 0.01 vs. H+R; hP, 0.05 vs. H+RLX+R.
Significance of differences for bax: aP , 0.001 vs. control; bP ,
0.001 vs. H; cP , 0.001 vs. H+RLX; dP , 0.001 vs. control
and P, 0.05 vs. H; eP, 0.001 vs. H+R; fP, 0.01 vs. RLX+H+R;
gP , 0.01 vs. H+R; hP , 0.05 vs. H+RLX+R.
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cardiomyocyte growth and maturation (33). In fact,
previous reports have shown that Notch-1 induces cell
cycle re-entry and proliferation of cardiac muscle cells
(43, 44). However, whether RLX may also be cardiopro-
tective through the recruitment of cardiac muscle
precursors in thepostinfarctedheart remains a stimulating
matter for further investigation.
Our findings indicate that the cytoprotection afforded
by RLX is more potent when the hormone was added
before the occurrence of hypoxia than at the onset of
reoxygenation. This notion, taken together with the
previous reports that cardiomyocytes produce RLX (10)
and express specific RLX receptors (11, 12), strongly
suggests that RLX could be an endogenous cardiac
factor involved in the mechanisms of myocardial pre-
conditioning. Further clues in support to this hypothesis
come from the observations that plasma RLX is
increased in patients with cardiac failure (56), suggesting
that RLX may be released from the injured heart as an
attempt to compensate for noxious conditions; and
Notch-1 signaling has been recognized as a major
endogenous mechanism involved in heart pre- and
postconditioning (28, 29). Nonetheless, RLX also ex-
erted a significant cytoprotective action when admin-
istered at reoxygenation, suggesting that it can
effectively counteract the acute cellular mechanisms
of reperfusion injury.
In conclusion, our study expands the knowledge of the
pharmacological properties of RLX as a cardioprotective
agent. Of note, phase 3 clinical trials performed on heart
failure patients have demonstrated that human recombi-
nant RLX, or serelaxin (Novartis, Basel, Switzerland),
significantly improved the hemodynamic parameters and
life expectancy of the treated patients compared with the
placebo group (57), thus emerging as a new drug for the
treatment of the failing heart. The existing experimental
background can justify the design of clinical trials to
explore whether RLX may be a new drug for the primary
and secondary prevention and therapy of ischemic heart
disease.
Figure 6. Evaluation of apoptotic H9c2 cells in the different experimental conditions. The percentage of TUNEL-positive cells was
increased on hypoxia (H) and reoxygenation (H+R). These changes were antagonized by RLX, given either 24 h before hypoxia
(RLX+H; RLX+H+R) or at reoxygenation (H+RLX+R). The Notch-1 inhibitor DAPT reduced the effects of RLX. Scale bars, 10 mm.
Replicates of the experiments (n) are indicated at the bottom of each column. Values are mean 6 SEM. Significance of differences:
aP, 0.001 vs. control; bP, 0.05 vs. H; cP, 0.05 vs. H+RLX; dP, 0.001 vs. control and P, 0.001 vs. H; eP, 0.001 vs. H+R; fP, 0.01 vs.
RLX+H+R; gP , 0.01 vs. H+R; hP , 0.05 vs. H+RLX+R.
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Figure 7. Notch-1 activation by RLX in H9c2 cells under the different experimental conditions. RLX induces a significant increase in
Notch-ICD, as revealed by confocal immunofluorescence (A) and Western blotting (B). DAPT caused a significant decrease of Notch-
ICD compared with the controls (A–B). Confocal immunofluorescence (C) and Western blotting analyses (D) also show that Notch-
ICD was down-regulated by hypoxia and, even more, by reoxygenation, whereas RLX, given either 24 h before hypoxia or at
reoxygenation, antagonized such an effect. Scale bar, 10 mm. Replicates of the experiments (n) are indicated at the bottom of each
column. Values are mean6 SEM. Significance of differences: A, B) aP , 0.001 vs. control; C) aP , 0.001 vs. control; bP , 0.001 vs. H;
cP, 0.001 vs. control and P, 0.05 vs. H; dP, 0.001 vs. H+R; eP, 0.05 vs. H+R; D) aP, 0.01 vs. control; bP, 0.05 vs. H; cP, 0.001 vs.
control and P , 0.01 vs. H; dP , 0.05 vs. H+R; eP , 0.01 vs. H+R.
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